Pancreatic Cancer
- Home
- Solutions
- By Diseases
- Accessory Digestive Gland Diseases
- Pancreatic Cancer
In the United States, pancreatic cancer is among the foremost causes of cancer death. Most individuals have metastatic disease which is either unresectable or too advanced to treat surgically. Protheragen is a dedicated research service provider focusing on comprehensive drug development services. We specialize in the research of pancreatic cancer and use science and innovation to improve therapeutic options for difficult gastrointestinal conditions.
Cases of pancreatic cancer are classified and further divided into several subtypes: ductal adenocarcinoma, acinar cell carcinoma, small glandular carcinoma, and small cell carcinoma.
The prognosis of pancreatic cancer is dire, and it is a rapidly progressing disease. The majority, about ninety percent of pancreatic cancers, are classified as pancreatic ductal adenocarcinoma (PDACs). Globally, the age-standardized incidence rate now stands and 5.7 per 100,000 person-years.
Fig.1 Incidence of pancreatic cancer. (Klein A. P., 2021)
Pancreatic cancer can be the outcome of familial germline or somatically acquired mutations in cancer-related genes which also cause the cancer to progress and spread. PDAC is mainly developed as a result of clonal selection of favorable somatic genetic mutations that occur during a person's life and can be initiated by tissue damage and modulated by germline risk variants, immune response, and some other factors. More than ninety percent of PDACs contain activating somatic mutations within the KRAS oncogene. Somatic mutations in the p16/CDKN2A, TP53, and SMAD4 tumor suppressor genes are also observed in 90%, 75%, and 50% of the cases, respectively.
Fig.2 Detection methods of pancreatic neoplasia. (Stoffel, E. M., et al., 2023)
| Drug Names | Mechanism of Action | Targets | NCT Number | Research Phase |
| GC203 TIL | An engineered tumor-infiltrating lymphocyte (TIL) to activate internal immune cells. | / | NCT06828328 | Phase I |
| Icaritin | Possess anti-cancer activity and downregulate the expression of TNF-α, IL-6, and PD-L1. | ERα | NCT06825546 | Phase III |
| IBI343 | Binding to CLDN18.2-expressing tumor cells, facilitating the internalization of the ADC. | CLDN18.2 | NCT06770439 | Phase II |
| CHT102 | A universal CAR-T therapy for mesothelin (MSLN) positive advanced solid tumors. | MSLN | NCT06760364 | Phase I |
| Polymeric Micellar Paclitaxel | Enhance the therapeutic effectiveness against tumors of paclitaxel by directly delivering it to the target region. | Tubulin | NCT06752811 | Phase III |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Deploying the latest technologies and methods, makes drug development services created by us an innovative endeavor. We appreciate particular challenges that pertain to rare gastrointestinal diseases like pancreatic cancer and offer tailored approaches - both in detail of specific research and therapeutic interventions, and provide a full range of services including diagnostics, therapeutics, and the development of disease models, ensuring a seamless drug development process.
Animal models are of great importance in studying the pathogenesis of disease and in testing new disease interventions. Our company has specific animal model development to study pancreatic cancer which allows efficient and accurate preclinical studies.
Animals with genetically engineered mutations in pancreatic cancer-related genes develop pancreatic tumors.
Optional models: KRAS mutation model, TP53 mutation model, etc.
The models of pancreatic tumors incurred in animals through induction with specific chemical carcinogens or other compounds.
Optional models: Cerulein-induced models, etc.
Implantation of mouse pancreatic cancer cell lines or tumor fragments into mice of the same strain.
Optional models: Mouse-derived allografts (MDAs), etc.
The xenograft models where PDAC cells are implanted into the animal by orthotopic or subcutaneous transplantation.
Optional models: Cell line-based xenograft models, patient-derived xenografts, etc.
Protheragen may help facilitate your primary research on pancreatic cancer by offering pharmacokinetic studies and drug safety evaluation services which aid in disease therapy facilitation. Join us and gain access to industry-leading services in drug development for rare gastrointestinal disorders. If you have any questions regarding these services, please do not hesitate to contact us for further details and the price outline.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.